It is worth noting that factors like tumor mutation burden, heterogeneity of PD-1 and CTLA-4 expression in host and malignant cells, and other patient-specific characteristics may influence a patient’s risk of experiencing neurologic irAEs. Here, CTLA4 is linked to neoplasm.